Michael Rosemore, DO
Physical Medicine & Rehabilitation · Bessemer, ALNPI 1104849843
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 644 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Among physical medicine & rehabilitation clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 644 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- GSK$1K
- AbbVie$1K
- Pfizer$791
- Boehringer Ingelheim$690
- AstraZeneca$639
- plus $4K from 40 others
What the payments were for
- Food & beverage$10,440100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$10,461 in reported general payments places this provider in the 95th percentile of 104 physical medicine & rehabilitation providers in Alabama.
See all physical medicine & rehabilitation providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 594 | $297,107 |
| OzempicSemaglutide | 94 | $95,589 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $72,368 |
| JardianceEmpagliflozin | 112 | $71,292 |
| RybelsusSemaglutide | 39 | $56,912 |
| XareltoRivaroxaban | 116 | $51,952 |
| JanuviaSitagliptin Phosphate | 85 | $43,860 |
| NuplazidPimavanserin Tartrate | 11 | $27,329 |
| MounjaroTirzepatide | 23 | $25,813 |
| TrulicityDulaglutide | 23 | $24,726 |
| FarxigaDapagliflozin Propanediol | 32 | $17,811 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $14,224 |
| InvokanaCanagliflozin | 14 | $13,957 |
| MyrbetriqMirabegron | 32 | $11,529 |
| Daptomycin | 30 | $10,882 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $791 | $301,038616 claims |
| Novo NordiskOzempic, Rybelsus | $1,610 | $152,501133 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,376 | $92,219142 claims |
| Boehringer IngelheimJardiance, Tradjenta | $690 | $79,018134 claims |
| Johnson & JohnsonXarelto, Invokana | $446 | $65,910130 claims |
| Lilly USA, LLCMounjaro, Trulicity | $376 | $50,53946 claims |
| MerckJanuvia, Janumet | $266 | $48,55697 claims |
| Acadia Pharmaceuticals IncNuplazid | $15 | $27,32911 claims |
| AstraZenecaFarxiga | $639 | $17,81132 claims |
| Astellas Pharma US IncMyrbetriq | $106 | $11,52932 claims |
| NovartisEntresto | $577 | $9,26016 claims |
| AbbVieCreon | $1,064 | $6,23312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 104 physical medicine & rehabilitation providers in Alabama.
Other physical medicine & rehabilitation in Bessemer
- Don McCormickBirmingham$22K
- Bradly GoodmanBirmingham$15K
- Nelson Santos AgostoBirmingham$14K
- John PantuoscoBirmingham$12K
- Ross LumsdenBirmingham$11K
- Stevon BoyettAthens$8K
- David ThomasonDaphne$7K
- Matthew BerkeBirmingham$6K
- Frederick GrahamNorthport$4K
- Jonathan RainerDaphne$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.